Cardiovascular AKT RACGP: Clinical Revision & Exam Guide

Cardiovascular medicine represents one of the highest-yield clinical domains in the RACGP Applied Knowledge Test (AKT). Because cardiovascular disease carries a significant burden of disease in the Australian population, examiners consistently blue-print multiple questions targeting hypertension, ischemic heart disease, atrial fibrillation, and heart failure.

Many candidates lose marks in this domain not because they fail to recognize major cardiac emergencies, but because they are unfamiliar with recent guideline shifts in primary care. In particular, the transition to the 2023 Australian Guideline for assessing and managing cardiovascular disease risk has introduced critical changes in screening age thresholds and therapeutic initiation rules that are heavily tested.

This clinical revision guide details the high-yield cardiovascular presentations you must master for the AKT, maps them to current Australian guidelines, and highlights the examiner-reported errors you must avoid to secure your passing score.

The 2023 CVD Risk Calculator: The New Standard

The 2023 Australian Guideline for assessing and managing cardiovascular disease risk replaced the old 2012 Framingham-based risk charts. This is a highly tested clinical update on the AKT. You must know the new age thresholds, risk categories, and treatment initiation rules.

Screening Age Thresholds

Under the 2023 guidelines, routine cardiovascular risk assessment is recommended for asymptomatic people without pre-existing CVD based on the following specific age criteria:

• General population: Start screening at age 45 to 74 years.
• First Nations people: Start screening at age 30 to 74 years.
• People with diabetes: Start screening at age 35 to 74 years.

Risk Categories and Reclassification

The 2023 calculator estimates the 5-year risk of a cardiovascular disease event (myocardial infarction, stroke, or cardiovascular death). The risk is categorized into three specific bands:

• Low risk: Less than 5% estimated 5-year CVD risk.
• Intermediate risk: 5% to less than 10% estimated 5-year risk.
• High risk: 10% or greater estimated 5-year risk.

Pharmacological Treatment Thresholds

The 2023 guidelines clarify when to initiate lipid-lowering and blood pressure-lowering therapies based on the calculated 5-year risk:

• High risk (10% or greater): Recommend starting both lipid-lowering and blood pressure-lowering therapies, alongside lifestyle modification.
• Intermediate risk (5% to less than 10%): Discuss starting therapies if there are enhancing risk factors (e.g., family history of premature CVD, severe mental illness, or chronic inflammatory conditions) or if clinic blood pressure is persistently 140/90 mmHg or greater.
• Low risk (less than 5%): Lifestyle modification is the primary intervention. Pharmacological therapy is not routinely initiated unless clinic blood pressure is persistently 160/100 mmHg or greater.

Hypertension Management: Guidelines and Titration

Hypertension questions on the AKT test your ability to diagnose accurately, perform appropriate baseline investigations, and titrate medications systematically based on clinical context.

Correct Diagnosis

Do not diagnose hypertension based on a single clinic reading unless the patient presents in hypertensive crisis (180/110 mmHg or greater) with target organ damage.

For clinic readings between 140/90 mmHg and 179/109 mmHg, the guideline-directed next step is to arrange ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) to confirm the diagnosis and rule out white-coat hypertension.

Baseline Investigations

Once hypertension is confirmed, you must perform baseline screening for target organ damage and secondary causes. Ensure your study checklist includes:

• Urinalysis and UACR: Screening for chronic kidney disease and microalbuminuria.
• Urea, electrolytes, and creatinine: Establishing baseline renal function and screening for primary aldosteronism or renal artery stenosis (renal impairment).
• Fasting lipids and glucose: Assessing overall cardiovascular risk and screening for diabetes.
• 12-lead ECG: Screening for left ventricular hypertrophy (LVH), myocardial ischemia, or conduction issues.

Step-wise Pharmacological Titration

Therapeutic Guidelines recommend four primary classes of antihypertensive drugs as first-line therapy:

1. ACE inhibitors (ACEi) or Angiotensin II Receptor Blockers (ARBs): Preferred in patients with diabetes, chronic kidney disease, or heart failure. Never combine an ACEi and an ARB.
2. Calcium Channel Blockers (CCBs): Long-acting dihydropyridines (e.g., amlodipine) are highly effective first-line agents, particularly in older patients.
3. Thiazide-like Diuretics: Low-dose indapamide is preferred over hydrochlorothiazide due to superior cardiovascular outcome data.
4. Beta-blockers: No longer considered first-line for uncomplicated hypertension due to inferior stroke prevention data. They are reserved for patients with specific compelling indications such as heart failure, atrial fibrillation, or recent myocardial infarction.

When titrating therapy, if the target blood pressure is not achieved on a standard dose of a single agent, the guideline-directed approach is to add a second agent from a complementary class rather than increasing the first agent to maximum dose. This strategy maximizes blood pressure reduction while minimizing dose-dependent side effects. A common complementary combination is an ACEi/ARB with a CCB or a thiazide-like diuretic.

Ischemic Heart Disease & Angina

Ischemic heart disease questions test your ability to manage chronic stable angina in primary care and to coordinate the acute response to suspected acute coronary syndromes (ACS).

Stable Angina Management

The goals of managing stable angina are to relieve symptoms and prevent cardiovascular events.

• Symptom relief (First-line): Short-acting sublingual glyceryl trinitrate (GTN) is prescribed to all patients for acute symptom relief. Standard first-line preventative therapy is a beta-blocker (e.g., metoprolol or atenolol) or a rate-limiting calcium channel blocker (e.g., diltiazem or verapamil). Rate-limiting calcium channel blockers must never be combined with beta-blockers due to the high risk of bradycardia and heart block.
• Event prevention: Aspirin 100mg daily is indicated for all patients with confirmed coronary artery disease, unless contraindicated. Statin therapy is initiated with a target LDL cholesterol of less than 1.8 mmol/L (or a reduction of at least 50% from baseline), in alignment with Australian secondary prevention guidelines.

Acute Coronary Syndrome (ACS) Primary Care Protocol

If a patient presents to your general practice clinic with chest pain suspicious of acute coronary syndrome, you must initiate the emergency protocol immediately.

Perform a 12-lead ECG within 10 minutes of presentation. Call 000 for emergency ambulance transfer. Administer aspirin 300mg orally (chewed) immediately, unless contraindicated. Administer sublingual GTN if the patient has active pain and is haemodynamically stable (systolic blood pressure greater than 90 mmHg).

Do not administer routine oxygen. Oxygen therapy is indicated only if the oxygen saturation is less than 93% on room air, or if the patient is in respiratory distress or shock.

Never allow a patient with suspected ACS to drive themselves to the hospital, and do not refer them with a standard GP letter without calling an ambulance.

Atrial Fibrillation: Stroke Prevention and Rate Control

Atrial fibrillation (AF) is a common arrhythmia in older patients. AKT questions focus on opportunistic screening, stroke risk stratification, and the choice between rate and rhythm control.

Opportunistic Screening

Current Australian guidelines recommend opportunistic screening for AF by pulse palpation or handheld ECG devices in all asymptomatic patients aged 65 years or older presenting to general practice. If an irregular pulse is detected, a formal 12-lead ECG must be performed to confirm the diagnosis.

Stroke Risk Stratification: CHA2DS2-VA

The CHA2DS2-VA score (which excludes the female gender modifier from the older CHA2DS2-VASc score to simplify clinical decision-making in Australia) is used to guide oral anticoagulation therapy in non-valvular AF:

• C: Congestive heart failure (1 point)
• H: Hypertension (clinic BP persistently greater than 140/90 mmHg) (1 point)
• A: Age 75 years or older (2 points)
• D: Diabetes mellitus (1 point)
• S: Stroke, transient ischemic attack (TIA), or systemic thromboembolism history (2 points)
• V: Vascular disease (previous myocardial infarction, peripheral arterial disease, or complex aortic plaque) (1 point)
• A: Age 65 to 74 years (1 point)

Anticoagulation Decisions

Oral anticoagulation is strongly recommended for a score of 2 or greater, as the benefit of stroke prevention outweighs the risk of bleeding. For a score of 1, oral anticoagulation should be considered based on individual bleeding risk and patient preference. It is not recommended for a score of 0.

First-line therapy for non-valvular AF is a Direct Oral Anticoagulant (DOAC), such as apixaban or rivaroxaban, due to a superior safety profile (lower risk of intracranial haemorrhage) and more predictable pharmacokinetics compared to warfarin. Warfarin remains indicated only for patients with valvular AF (moderate-to-severe mitral stenosis or mechanical prosthetic heart valves) or severe renal impairment (creatinine clearance less than 15 mL/min).

Rate vs Rhythm Control

For the majority of patients with AF, a rate control strategy is first-line. The target resting heart rate is less than 110 bpm in asymptomatic patients with preserved left ventricular function. First-line rate-control agents include beta-blockers (e.g., metoprolol or bisoprolol) and rate-limiting calcium channel blockers (e.g., diltiazem or verapamil, which must be avoided in patients with systolic heart failure). Digoxin is reserved as third-line therapy, or in sedentary patients, or in combination with a beta-blocker when target heart rate is not achieved.

A rhythm control strategy (using electrical or chemical cardioversion, or antiarrhythmic drugs like amiodarone or flecainide, or catheter ablation) is reserved for patients who remain symptomatic despite adequate rate control, younger patients, or patients where AF is causing tachycardia-mediated cardiomyopathy.

Heart Failure: Classification and Pharmacological Management

Heart failure (HF) classification and the stepwise management of heart failure with reduced ejection fraction (HFrEF) are high-frequency topics on the AKT.

Classification by Ejection Fraction

Heart failure is classified based on left ventricular ejection fraction (LVEF) determined by echocardiography:

• HFrEF (Heart Failure with Reduced Ejection Fraction): LVEF of 40% or less.
• HFmrEF (Heart Failure with Mildly Reduced Ejection Fraction): LVEF of 41% to 49%.
• HFpEF (Heart Failure with Preserved Ejection Fraction): LVEF of 50% or greater.

Step-wise HFrEF Pharmacological Management

For patients with HFrEF (LVEF of 40% or less), guideline-directed medical therapy (GDMT) consists of four foundational drug classes, often referred to as the "four pillars." These agents should be initiated and uptitrated to target doses as tolerated:

1. ACE inhibitor (ACEi) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI): Sacubitril/valsartan (ARNI) is preferred over an ACEi as first-line therapy, or as a switch for patients who remain symptomatic on an ACEi, to further reduce mortality and hospitalisation. A 36-hour washout period is mandatory when switching from an ACEi to an ARNI to avoid life-threatening angioedema.
2. Beta-blocker: Only three beta-blockers have proven mortality benefit in HFrEF: bisoprolol, carvedilol, and sustained-release metoprolol succinate. Metoprolol tartrate does not have mortality data in heart failure and should not be used.
3. Mineralocorticoid Receptor Antagonist (MRA): E.g., spironolactone or eplerenone. Renal function and potassium levels must be monitored closely.
4. SGLT2 inhibitor: Dapagliflozin or empagliflozin. These agents reduce heart failure hospitalisation and cardiovascular mortality in patients with HFrEF, regardless of whether the patient has type 2 diabetes.

Fluid overload symptoms are managed with loop diuretics (e.g., frusemide or bumetanide). Loop diuretics are essential for symptom control but do not carry a mortality benefit. Once euvolemia is achieved, the dose of loop diuretic should be titrated down to the lowest effective maintenance dose.

Top 5 Examiner-Reported Cardiovascular Errors

Official RACGP public exam reports highlight specific recurring mistakes that candidates make in cardiovascular questions. Reviewing these errors will prevent you from losing straightforward marks.

1. 1
   Prescribing Rate-Limiting Calcium Channel Blockers in HFrEF

   Candidates often select verapamil or diltiazem for rate control in atrial fibrillation or for angina management in a patient who also has heart failure with reduced ejection fraction. These medications are negative inotropes and are strictly contraindicated in HFrEF as they can precipitate acute decompensated heart failure. Amlodipine, a dihydropyridine, is safe if a calcium channel blocker is required.

2. 2
   Neglecting the 36-Hour Washout Period Between ACEi and ARNI

   When switching a heart failure patient from an ACE inhibitor (e.g., ramipril) to sacubitril/valsartan, candidates frequently select an immediate switch. This is a severe clinical error. You must implement a mandatory 36-hour washout period after the last dose of the ACE inhibitor before starting the ARNI to prevent the accumulation of bradykinin and the development of severe angioedema. No washout period is required when switching from an ARB to an ARNI.

3. 3
   Selecting Metoprolol Tartrate for Heart Failure Management

   Under exam pressure, candidates often select metoprolol tartrate when asked to choose appropriate beta-blocker therapy for HFrEF. Only metoprolol succinate (controlled-release), carvedilol, and bisoprolol are approved for heart failure as they have proven mortality benefit. Metoprolol tartrate is short-acting and does not have mortality data in heart failure.

4. 4
   Misapplying the 2023 CVD Risk Calculator Age Limits

   Candidates sometimes select routine cardiovascular risk assessments for a healthy 38-year-old asymptomatic general patient or fail to initiate early screening for an asymptomatic 32-year-old First Nations patient. You must memorize the specific screening thresholds: age 45 for the general population, age 30 for First Nations people, and age 35 for people with diabetes.

5. 5
   Ordering Outpatient Investigations for Suspected ACS

   A common error is selecting outpatient cardiac troponin testing or referring a patient with suspected unstable angina or myocardial infarction for an urgent outpatient cardiologist review. Any patient with chest pain suspicious of acute coronary syndrome must be managed as an emergency, with an immediate ambulance transfer called from the clinic rooms.

Frequently Asked Questions